Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

SUNRISE supports tezepelumab in severe OCS-dependent asthma
24 Sep 2026
bởiAudrey Abella
In the phase III SUNRISE trial, tezepelumab significantly reduces daily maintenance oral corticosteroid (OCS) dose while maintaining asthma control in adults with severe OCS-dependent asthma, despite early study termination and the smaller-than-planned sample size.
24 Sep 2026







